IFN-α-Konsolidierung nach intensiver Chemotherapie bringt keinen Überlebensvorteil bei niedrigmalignen Non-Hodgkin-Lymphomen

Aviles A, Duque G, et al. Interferon alpha 2b as maintenance therapy in Low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 1996;20:495–9. Fisher RI, Dana BW, Michael LeBtanc M, et al. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with Low-grade non-Hodgkin's lym phoma: Results of the Southwest Oncology Group randomized phase III study 8809. J CLin Oncol 2000:18:2010–6. Peterson BA, Petroni G. Oken MM. et al. Cyclophosphamide versus cyclophosphamide plus interferon atfa-2b in follicular low grade Lymphomas. A preliminary report of an intergroup trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 1993:12:366.abstract 1240. Rohatiner AZS, Crowther D, Radfort JOA, et al. The role of interferon on follicular lymphoma. Proc Am Soc CLin Oncol 1996;15:418-abstract 12B5. Smalley RV, Andersen JW, Hawkins MJ, et al. Interferon alpha combined with cytotoxic chemotherapy far patients with non-Hodgkin's lymphoma. N Engl J Med 1992;327:1336–41. Solar-Celigny P, Lepage E, Brousse N, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993;329:1608–14. Solal-Celigny P, Lepage E, Brousse N. et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular Lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomas Folliculaires 86 Trial. J Clin Oncol 1998;16:2332–8. Unterhalt M, Herrmann R, Nahler M, et al. Significant prolongation of disease free survival in advanced low grade non Hodgkin lymphomas by interferon alpha maintenance. Blood 1995;86:439.abstract 1744.